Blog

Advanced NSCLC Trials Demonstrate Potential of First-Line Immunotherapy – GenomeWeb

Advanced NSCLC Trials Demonstrate Potential of First-Line Immunotherapy
GenomeWeb
These results suggest the anti-PD-1 checkpoint immunotherapy conferred some benefit as a front-line monotherapy, even for advanced NSCLC cases with relatively low levels of PD-L1, Lopes said during an ASCO press briefing over the weekend.

and more »

2018-06-05 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.